Year None20242023202220212020 NEWS RELEASE 10.15.2024 AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024 NEWS RELEASE 10.01.2024 LA LA ANTHONY PARTNERS WITH AMGEN TO SHARE CANDID, BEHIND-THE-SCENES LOOK AT HOW PLAQUE PSORIASIS AFFECTS HER LIFE NEWS RELEASE 09.24.2024 TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE NEWS RELEASE 09.23.2024 AMGEN TO HOST CONFERENCE CALL TO DISCUSS NEW TOPLINE DATA IN INFLAMMATION AND RARE DISEASE NEWS RELEASE 09.13.2024 AMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024 NEWS RELEASE 09.09.2024 AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024 NEWS RELEASE 08.30.2024 AMGEN TO PRESENT AT THE 2024 WELLS FARGO HEALTHCARE CONFERENCE NEWS RELEASE 08.29.2024 AMGEN TO PRESENT AT THE MORGAN STANLEY 22ND ANNUAL GLOBAL HEALTHCARE CONFERENCE NEWS RELEASE 08.20.2024 OTEZLA® (APREMILAST) NOW AVAILABLE IN THE U.S. FOR MODERATE TO SEVERE PEDIATRIC PLAQUE PSORIASIS NEWS RELEASE 08.06.2024 AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS NEWS RELEASE 08.02.2024 AMGEN ANNOUNCES 2024 THIRD QUARTER DIVIDEND NEWS RELEASE 08.01.2024 AMGEN ANNOUNCES WEBCAST OF 2024 SECOND QUARTER FINANCIAL RESULTS NEWS RELEASE 06.14.2024 FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE NEWS RELEASE 06.12.2024 AMGEN TO PRESENT INNOVATIVE RHEUMATOLOGY RESEARCH AT EULAR 2024 NEWS RELEASE 06.05.2024 AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE NEWS RELEASE 06.05.2024 AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD) NEWS RELEASE 06.03.2024 AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE NEWS RELEASE 05.28.2024 AMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024 NEWS RELEASE 05.19.2024 NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD NEWS RELEASE 05.16.2024 FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER NEWS RELEASE 05.15.2024 AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024 NEWS RELEASE 05.09.2024 AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE NEWS RELEASE 05.02.2024 AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS NEWS RELEASE 05.01.2024 AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024 NEWS RELEASE 04.29.2024 AMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS NEWS RELEASE 04.26.2024 AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY NEWS RELEASE 04.16.2024 AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024 NEWS RELEASE 03.09.2024 AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024 NEWS RELEASE 03.06.2024 AMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND NEWS RELEASE 02.29.2024 AMGEN TO PRESENT AT THE 44TH ANNUAL TD COWEN HEALTH CARE CONFERENCE NEWS RELEASE 02.26.2024 AMGEN OPENS STATE-OF-THE-ART BIOMANUFACTURING SITE IN CENTRAL OHIO NEWS RELEASE 02.19.2024 AMGEN TO HOST CONFERENCE CALL ON RARE DISEASE NEWS RELEASE 02.09.2024 AMGEN TO PRESENT AT THE 34TH ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE NEWS RELEASE 02.06.2024 AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS NEWS RELEASE 02.01.2024 AMGEN ANNOUNCES WEBCAST OF 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS NEWS RELEASE 01.03.2024 AMGEN TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE